Exclusive

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

by Nile
August 17, 2020

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life… Read More »BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

Insights+ Exclusive: COVID-19 Healthcare News Monthly Updates – July 2020

by Nile
July 31, 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019”… Read More »Insights+ Exclusive: COVID-19 Healthcare News Monthly Updates – July 2020

Insights+ Exclusive: The US FDA New Drug Approvals in June 2020

by Nile
July 24, 2020

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products… Read More »Insights+ Exclusive: The US FDA New Drug Approvals in June 2020